Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02475213
Recruitment Status : Completed
First Posted : June 18, 2015
Last Update Posted : September 28, 2021
Information provided by (Responsible Party):